Gilead has filed the first interferon-free hepatitis C virus regimen for approval in the United States, but drug developers are making strides with better combinations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Tse, M. All-oral HCV therapies near approval. Nat Rev Drug Discov 12, 409–411 (2013). https://doi.org/10.1038/nrd4036
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4036
This article is cited by
-
Conformational flexibility of DENV NS2B/NS3pro: from the inhibitor effect to the serotype influence
Journal of Computer-Aided Molecular Design (2016)
-
2014 FDA drug approvals
Nature Reviews Drug Discovery (2015)
-
Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase
Molecular Diversity (2015)